Javascript must be enabled to continue!
Reporting and Analyzing Race and Ethnicity in Orthopaedic Clinical Trials: A Systematic Review
View through CrossRef
Background:
The distinction between race and ethnicity should be carefully understood and described for demographic data collection. Racial healthcare differences have been observed across many orthopaedic subspecialties. However, the frequency of reporting and analyzing race and ethnicity in orthopaedic clinical trials has not been determined. Therefore, the primary purpose of this systematic review was to determine how frequently race and ethnicity are reported and analyzed in orthopaedic clinical trials.
Methods:
The top 10 journals by impact factor in the field of orthopaedics were manually screened from 2015 to 2019. All randomized controlled trials related to orthopaedics and assessing clinical outcomes were included. Eligible studies were evaluated for bias using the Cochrane risk-of-bias tool and for whether the trial reported and analyzed several demographics, including age, sex, height, weight, race, and ethnicity. The frequency of reporting and analyzing by each demographic was accessed. In addition, comparisons of reporting and analyzing race/ethnicity were made based on orthopaedic subspecialty and journal of publication.
Results:
A total of 15,488 publications were screened and 482 met inclusion criteria. Of these 482 trials, 460 (95.4%) reported age and 456 (94.6%) reported sex, whereas 35 (7.3%) reported race and 15 (3.1%) reported ethnicity for the randomized groups; 79 studies (16.4%) analyzed age and 72 studies (14.9%) analyzed sex, whereas 6 studies (1.2%) analyzed race and 1 study (0.2%) analyzed ethnicity. The orthopaedic subspecialty of spine was found to report race (23.5%) and ethnicity (17.6%) more frequently than all the other subspecialties, whereas sports medicine reported race and/or ethnicity in only 3 of 150 trials (2.0%).
Conclusions:
Race and ethnicity are not frequently reported or analyzed in orthopaedic randomized controlled trials. Social context, personal challenges, and economic challenges should be considered while analyzing the effect of race and ethnicity on outcomes.
Ovid Technologies (Wolters Kluwer Health)
Title: Reporting and Analyzing Race and Ethnicity in Orthopaedic Clinical Trials: A Systematic Review
Description:
Background:
The distinction between race and ethnicity should be carefully understood and described for demographic data collection.
Racial healthcare differences have been observed across many orthopaedic subspecialties.
However, the frequency of reporting and analyzing race and ethnicity in orthopaedic clinical trials has not been determined.
Therefore, the primary purpose of this systematic review was to determine how frequently race and ethnicity are reported and analyzed in orthopaedic clinical trials.
Methods:
The top 10 journals by impact factor in the field of orthopaedics were manually screened from 2015 to 2019.
All randomized controlled trials related to orthopaedics and assessing clinical outcomes were included.
Eligible studies were evaluated for bias using the Cochrane risk-of-bias tool and for whether the trial reported and analyzed several demographics, including age, sex, height, weight, race, and ethnicity.
The frequency of reporting and analyzing by each demographic was accessed.
In addition, comparisons of reporting and analyzing race/ethnicity were made based on orthopaedic subspecialty and journal of publication.
Results:
A total of 15,488 publications were screened and 482 met inclusion criteria.
Of these 482 trials, 460 (95.
4%) reported age and 456 (94.
6%) reported sex, whereas 35 (7.
3%) reported race and 15 (3.
1%) reported ethnicity for the randomized groups; 79 studies (16.
4%) analyzed age and 72 studies (14.
9%) analyzed sex, whereas 6 studies (1.
2%) analyzed race and 1 study (0.
2%) analyzed ethnicity.
The orthopaedic subspecialty of spine was found to report race (23.
5%) and ethnicity (17.
6%) more frequently than all the other subspecialties, whereas sports medicine reported race and/or ethnicity in only 3 of 150 trials (2.
0%).
Conclusions:
Race and ethnicity are not frequently reported or analyzed in orthopaedic randomized controlled trials.
Social context, personal challenges, and economic challenges should be considered while analyzing the effect of race and ethnicity on outcomes.
Related Results
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
This review summarizes the evidence from six randomized controlled trials that judged the effectiveness of systematic review summaries on policymakers' decision making, or the most...
Mindy Calling: Size, Beauty, Race in The Mindy Project
Mindy Calling: Size, Beauty, Race in The Mindy Project
When characters in the Fox Television sitcom The Mindy Project call Mindy Lahiri fat, Mindy sees it as a case of misidentification. She reminds the character that she is a “petite ...
Representation of women in orthopaedic surgery: perception of barriers among undergraduate medical students in Saudi Arabia
Representation of women in orthopaedic surgery: perception of barriers among undergraduate medical students in Saudi Arabia
Abstract
Background
While female participation has improved in several surgical specialties over time globally, no such increase has been observed i...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
ABSTRACT
Background
Research infra-structure is essential for conducting phase III cancer clinical trials as its lack precludes...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...

